Abstract
Catecholamines stimulate cardiac contractility through β1-adrenergic receptors (β1-ARs), which in humans are polymorphic at amino acid residue 389 (Arg/Gly). We used cardiac-targeted transgenesis in a mouse model to delineate mechanisms accounting for the association of Arg389 with human heart failure phenotypes. Hearts from young Arg389 mice had enhanced receptor function and contractility compared with Gly389 hearts. Older Arg389 mice displayed a phenotypic switch, with decreased β-agonist signaling to adenylyl cyclase and decreased cardiac contractility compared with Gly 389 hearts. Arg389 hearts had abnormal expression of fetal and hypertrophy genes and calcium-cycling proteins, decreased adenylyl cyclase and Gαs expression, and fibrosis with heart failure This phenotype was recapitulated in homozygous, end-stage, failing human hearts. In addition, hemodynamic responses to β-receptor blockade were greater in Arg389 mice, and homozygosity for Arg389 was associated with improvement in ventricular function during carvedilol treatment in heart failure patients. Thus the human Arg389 variant predisposes to heart failure by instigating hyperactive signaling programs leading to depressed receptor coupling and ventricular dysfunction, and influences the therapeutic response to β-receptor blockade.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Givertz, M.M. Underlying causes and survival in patients with heart failure. N. Engl. J. Med. 342, 1120–1122 (2000).
van Campen, L.C., Visser, F.C. & Visser, C.A. Ejection fraction improvement by beta-blocker treatment in patients with heart failure: an analysis of studies published in the literature. J. Cardiovasc. Pharmacol. 32 (suppl. 1), S31–S35 (1998).
Franz, W.-M., Müller, O.J. & Katus, H.A. Cardiomyopathies: from genetics to the prospect of treatment. Lancet 358, 1627–1637 (2001).
Engelhardt, S., Hein, L., Wiesmann, F. & Lohse, M.J. Progressive hypertrophy and heart failure in beta1-adrenergic receptor transgenic mice. Proc. Natl. Acad. Sci. USA 96, 7059–7064 (1999).
Liggett, S.B. β-adrenergic receptors in the failing heart: the good, the bad, and the unknown. J. Clin. Invest. 107, 947–948 (2001).
Mason, D.A., Moore, J.D., Green, S.A. & Liggett, S.B. A gain-of-function polymorphism in a G-protein coupling domain of the human β1-adrenergic receptor. J. Biol. Chem. 274, 12670–12674 (1999).
Moore, J.D., Mason, D.A., Green, S.A., Hsu, J. & Liggett, S.B. Racial differences in the frequencies of cardiac β1-adrenergic receptor polymorphisms: analysis of c145A>G and c1165G>C. Hum. Mutat. 14, 271–271 (1999).
Palczewski, K. et al. Crystal structure of rhodopsin: a G protein-coupled receptor. Science 289, 739–745 (2000).
Small, K.M., Wagoner, L.E., Levin, A.M., Kardia, S.L.R. & Liggett, S.B. Synergistic polymorphisms of β1- and α2C-adrenergic receptors and the risk of congestive heart failure. N. Engl. J. Med. 347, 1135–1142 (2002).
Wagoner, L.E. et al. Polymorphisms of the β1-adrenergic receptor predict exercise capacity in heart failure. Am. Heart J. 144, 840–846 (2002).
Bengtsson, K. et al. Polymorphism in the β1-adrenergic receptor gene and hypertension. Circulation 104, 187–190 (2001).
D'Angelo, D.D. et al. Transgenic Gαq overexpression induces cardiac contractile failure in mice. Proc. Natl. Acad. Sci. USA 94, 8121–8126 (1997).
Liggett, S.B. et al. Early and delayed consequences of β2-adrenergic receptor overexpression in mouse hearts. Circulation 101, 1707–1714 (2000).
Bristow, M.R. et al. Decreased catecholamine sensitivity and β-adrenergic-receptor density in failing human hearts. N. Engl. J. Med. 307, 205–211 (1982).
Bristow, M.R., Hershberger, R.E., Port, J.D., Minobe, W. & Rasmussen, R. β1- and β2-adrenergic receptor-mediated adenylate cyclase stimulation in nonfailing and failing human ventricular myocardium. Mol. Pharmacol. 35, 295–303 (1988).
Dunigan, C.D., Hoang, Q., Curran, P.K. & Fishman, P.H. Complexity of agonist- and cyclic AMP-mediated downregulation of the human β1-adrenergic receptor: role of internalization, degradation, and mRNA destabilization. Biochem. 41, 8019–8030 (2002).
Dorn, G.W.I., Tepe, N.M., Wu, G., Yatani, A. & Liggett, S.B. Mechanisms of impaired β-adrenergic receptor signaling in Gαq-mediated cardiac hypertrophy and ventricular dysfunction. Mol. Pharmacol. 57, 278–287 (2000).
Bohm, M. et al. Desensitization of adenylate cyclase and increase of Gi alpha in cardiac hypertrophy due to acquired hypertension. Hypertension 20, 103–112 (1992).
Ungerer, M., Bohm, M., Elce, J.S., Erdmann, E. & Lohse, M.J. Altered expression of beta-adrenergic receptor kinase and β1-adrenergic receptors in the failing human heart. Circulation 87, 454–463 (1993).
Bohm, M. et al. Increase of Gi alpha in human hearts with dilated but not ischemic cardiomyopathy. Circulation 82, 1249–1265 (1990).
Eschenhagen, T. et al. Increased messenger RNA level of the inhibitory G protein α subunit Giα-2 in human end-stage heart failure. Circ. Res. 70, 688–696 (1992).
Packer, M. et al. Effect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the carvedilol prospective randomized cumulative survival (COPERNICUS) study. Circulation 106, 2164–2166 (2002).
Bristow, M.R. et al. β1- and β2-adrenergic-receptor subpopulations in nonfailing and failing human ventricular myocardium: coupling of both receptor subtypes to muscle contraction and selective β1-receptor downregulation in heart failure. Circ. Res. 59, 297–309 (1986).
Rathz, D.A., Gregory, K.N., Fang, Y., Brown, K.M. & Liggett, S.B. Hierarchy of polymorphic variation and desensitization permutations relative to β1- and β2-adrenergic receptor signaling. J. Biol. Chem. 278, 10784–10789 (2003).
Yussman, M.G. et al. Mitochondrial death protein Nix is induced in cardiac hypertrophy and triggers apoptotic cardiomyopathy. Nat. Med. 8, 725–730 (2002).
Serikov, V.B., Petrashevskaya, N.N., Canning, A.M. & Schwartz, A. Reduction of [Ca2+]i restores uncoupled beta-adrenergic signaling in isolated perfused transgenic mouse hearts. Circ. Res. 88, 9–11 (2001).
Tepe, N.M. et al. Altering the receptor-effector ratio by transgenic overexpression of type V adenylyl cyclase: enhanced basal catalytic activity and function without increased cardiomyocyte β-adrenergic signalling. Biochemistry 38, 16706–16713 (1999).
Small, K.M., Rathz, D.A. & Liggett, S.B. Identification of adrenergic receptor polymorphisms. Methods Enzymol. 343, 459–475 (2002).
Wagoner, L.E. et al. Polymorphisms of the β2-adrenergic receptor determine exercise capacity in patients with heart failure. Circ. Res. 86, 834–840 (2000).
Acknowledgements
This work was supported by National Institutes of Health grants HL22619, HL52318 and ES06096.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Rights and permissions
About this article
Cite this article
Perez, J., Rathz, D., Petrashevskaya, N. et al. β1-adrenergic receptor polymorphisms confer differential function and predisposition to heart failure. Nat Med 9, 1300–1305 (2003). https://doi.org/10.1038/nm930
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/nm930
This article is cited by
-
Towards precision medicine in heart failure
Nature Reviews Cardiology (2021)
-
Ex Ante Economic Evaluation of Arg389 Genetically Targeted Treatment with Bucindolol versus Empirical Treatment with Carvedilol in NYHA III/IV Heart Failure
American Journal of Cardiovascular Drugs (2021)
-
ADRB2 polymorphism Arg16Gly modifies the natural outcome of heart failure and dictates therapeutic response to β-blockers in patients with heart failure
Cell Discovery (2018)
-
Mechanisms of signalling and biased agonism in G protein-coupled receptors
Nature Reviews Molecular Cell Biology (2018)
-
Genetic Predispositions to Heart Failure
Current Cardiovascular Risk Reports (2016)